Cargando…

Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands

BACKGROUND: Gefitinib, a tyrosine kinase inhibitor, is an effective treatment in advanced non-small cell lung cancer (NSCLC) patients with an activating mutation in the epidermal growth factor receptor (EGFR). Randomised clinical trials showed a benefit in progression free survival for gefitinib ver...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verduyn, S Cora, Biesma, Bonne, Schramel, Franz MNH, van der Scheer, Feike W, Langenfeld, Merel K, de Peuter, Maria A, Dingemans, Anne-Marie C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492197/ https://www.ncbi.nlm.nih.gov/pubmed/22963131 http://dx.doi.org/10.1186/1477-7525-10-108

Ejemplares similares

Website Visitors Asking Questions Online to Lung Cancer Specialists: What Do They Want To Know?
por: Schook, Romane M, et al.
Publicado: (2013)

Efficacy of Ibandronate Loading Dose on Rapid Pain Relief in Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: The NVALT-9 Trial
por: Brouns, Anita J. W. M., et al.
Publicado: (2020)

‘Care for Outcomes’: systematic development of a set of outcome indicators to improve patient-relevant outcomes for patients with lung cancer
por: Cramer-van der Welle, Christine M, et al.
Publicado: (2021)

Why Do Patients and Caregivers Seek Answers From the Internet and Online Lung Specialists? A Qualitative Study
por: Schook, Romane Milia, et al.
Publicado: (2014)

Age- and gender-adjusted eGFR to estimate baseline creatinine for RIFLE criteria
por: Spoorenberg, Simone M. C., et al.
Publicado: (2011)

The estimated disease burden of acute COVID-19 in the Netherlands in 2020, in disability-adjusted life-years
por: McDonald, Scott A., et al.
Publicado: (2022)

Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands
por: Cramer-van der Welle, Christine M., et al.
Publicado: (2021)

Systematic evaluation of the efficacy–effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer
por: Cramer-van der Welle, Christine M., et al.
Publicado: (2018)

A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment
por: Wachters, F M, et al.
Publicado: (2005)

Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs
por: Zhu, Yan-juan, et al.
Publicado: (2017)

Bone Morphogenetic Protein Type I Receptor Antagonists Decrease Growth and Induce Cell Death of Lung Cancer Cell Lines
por: Langenfeld, Elaine, et al.
Publicado: (2013)

Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy
por: Huisman, C, et al.
Publicado: (2001)

Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study
por: Groen, Harry J. M., et al.
Publicado: (2019)

Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014
por: Cramer-van der Welle, Christine M., et al.
Publicado: (2020)

Adjusting line quantum sensing to improve leaf area index measurements and estimations in forests
por: Battuvshin, Guyen, et al.
Publicado: (2022)

Traumatic Brain Injury in the Netherlands: Incidence, Costs and Disability-Adjusted Life Years
por: Scholten, Annemieke C., et al.
Publicado: (2014)

Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands
por: Mfumbilwa, Zakile A., et al.
Publicado: (2023)

Adjustment of the working lines in the ISR
por: Gourber, J P, et al.
Publicado: (1971)

Estimated incubation period for monkeypox cases confirmed in the Netherlands, May 2022
por: Miura, Fuminari, et al.
Publicado: (2022)

Incidence of Symptomatic Submucous Cleft Palate in the Netherlands: A Retrospective Cohort Study Over a Period of 22 Years
por: Smit, Johannes A., et al.
Publicado: (2020)

Neural networks for self-adjusting mutation rate estimation when the recombination rate is unknown
por: Burger, Klara Elisabeth, et al.
Publicado: (2022)

Quality-Adjusted Life-Years Lost Due to COVID-19 Mortality: Methods and Application for The Netherlands
por: Wouterse, Bram, et al.
Publicado: (2022)

LINE-1 Hypermethylation in Serum Cell-Free DNA of Relapsing Remitting Multiple Sclerosis Patients
por: Dunaeva, Marina, et al.
Publicado: (2017)

Impact of severe necrotizing fasciitis on quality of life in the Netherlands
por: van Stigt, Sander F. L., et al.
Publicado: (2022)

Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
por: Barretina-Ginesta, Maria-Pilar, et al.
Publicado: (2022)

Compliance to DMD Care Considerations in the Netherlands
por: Heutinck, Lotte, et al.
Publicado: (2021)

Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands
por: Broers, Merel C., et al.
Publicado: (2022)

Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity
por: van den Broek, Daan, et al.
Publicado: (2020)

An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA)
por: Bullement, Ash, et al.
Publicado: (2021)

Small-bowel Diverticulosis:Imaging Findings and Review of Three Cases
por: De Peuter, B., et al.
Publicado: (2009)

Tuberculosis contact investigation following the stone-in-the-pond principle in the Netherlands – Did adjusted guidelines improve efficiency?
por: van de Berg, Sarah, et al.
Publicado: (2021)

Should adjustment for covariates be used in prevalence estimations?
por: Li, Wenjun, et al.
Publicado: (2008)

Estimating Health Adjusted Age at Death (HAAD)
por: Johansson, Kjell Arne, et al.
Publicado: (2020)

On-line health companion contact among chronically ill in the Netherlands
por: Dumaij, Adrie C. M., et al.
Publicado: (2011)

An evidence synthesis approach to estimating the incidence of seasonal influenza in the Netherlands
por: McDonald, Scott A, et al.
Publicado: (2014)

Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease)
por: Phernambucq, E C J, et al.
Publicado: (2006)

Prioritizing Emerging Zoonoses in The Netherlands
por: Havelaar, Arie H., et al.
Publicado: (2010)

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
por: Hondelink, Liesbeth M., et al.
Publicado: (2021)

Diffusion of smoke-free policies at outdoor sports clubs in the Netherlands
por: Garritsen, HH, et al.
Publicado: (2022)

A Novel Procedure for Knee Flexion Angle Estimation Based on Functionally Defined Coordinate Systems and Independent of the Marker Landmarks
por: Ancillao, Andrea, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g4g5jju93egbv6qoucbgtievcv